Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.227 EUR
−22.33 M EUR
1.18 M EUR
34.63 M
About TRANSGENE
Sector
Industry
CEO
Alessandro Riva
Website
Headquarters
Strasbourg
Founded
1979
ISIN
FR0005175080
FIGI
BBG00JHW1490
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. Its products include TG4001, TG4050, TG6002, BT-001 & TG6050. The company was founded in December 1979 and is headquartered in Strasbourg, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0OCQ is 0.683 EUR — it has decreased by −2.11% in the past 24 hours. Watch TRANSGENE EUR0.50 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange TRANSGENE EUR0.50 stocks are traded under the ticker 0OCQ.
0OCQ stock has fallen by −1.69% compared to the previous week, the month change is a −9.61% fall, over the last year TRANSGENE EUR0.50 has showed a −49.18% decrease.
We've gathered analysts' opinions on TRANSGENE EUR0.50 future price: according to them, 0OCQ price has a max estimate of 2.60 EUR and a min estimate of 2.00 EUR. Watch 0OCQ chart and read a more detailed TRANSGENE EUR0.50 stock forecast: see what analysts think of TRANSGENE EUR0.50 and suggest that you do with its stocks.
0OCQ reached its all-time high on Jan 25, 2018 with the price of 3.282 EUR, and its all-time low was 0.699 EUR and was reached on Dec 24, 2024. View more price dynamics on 0OCQ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0OCQ stock is 4.10% volatile and has beta coefficient of 0.98. Track TRANSGENE EUR0.50 stock price on the chart and check out the list of the most volatile stocks — is TRANSGENE EUR0.50 there?
Today TRANSGENE EUR0.50 has the market capitalization of 92.63 M, it has decreased by −2.25% over the last week.
Yes, you can track TRANSGENE EUR0.50 financials in yearly and quarterly reports right on TradingView.
TRANSGENE EUR0.50 is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
0OCQ net income for the last half-year is −16.48 M EUR, while the previous report showed −6.43 M EUR of net income which accounts for −156.54% change. Track more TRANSGENE EUR0.50 financial stats to get the full picture.
No, 0OCQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 31, 2024, the company has 158.00 employees. See our rating of the largest employees — is TRANSGENE EUR0.50 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRANSGENE EUR0.50 EBITDA is −36.17 M EUR, and current EBITDA margin is −2.86 K%. See more stats in TRANSGENE EUR0.50 financial statements.
Like other stocks, 0OCQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRANSGENE EUR0.50 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRANSGENE EUR0.50 technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRANSGENE EUR0.50 stock shows the sell signal. See more of TRANSGENE EUR0.50 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.